NHS rolls out fast tracked immunotherapy for advanced endometrial cancer

Immunotherapy dostarlimab (Jemperli) will be available on the NHS for patients with advanced primary or recurrent endometrial cancer after trial results showed that it can slow the spread of the cancer when added to chemotherapy.The immunotherapy, which can provide patients with “significant extra time before their disease progresses” compared with chemotherapy alone, could help an estimated 150 to 200 women each year, NHS England has said.Clinical trial results showed that almost two thirds (64%) of patients who received dostarlimab plus chemotherapy had not seen their cancer progress after 12 months of treatment. This was more than twice the rate seen in patients treated with chemotherapy alone (24%).Rollout of dostarlimab, which has been approved by the National Institute for Health and Care Excellence (NICE),1 was fast tracked by NHS England through its Cancer Drugs Fund. This provides patients with early access to promising treatments while further evidence on its benefits and…
Read Original Article: NHS rolls out fast tracked immunotherapy for advanced endometrial cancer »